Oncology Voice Network
Join the Oncology Voice Network. Join for Free
All about Job Offers and what to be aware of
job offer negotiations compensation discussions employment agreements non-compete agreements sign-on bonuses

All about Job Offers and what to be aware of

  • Aug 17th 2021
  • 41 mins
  • E66

Share This Article

Summary

E66 • Aug 17, 2021 • 41 mins

In this episode, Tom Caravela welcomes Anthony Greco to discuss job offer negotiations. Anthony shares insights on clear communication and understanding legal aspects during compensation discussions. They explore the risks of over-negotiation and emphasize early talks on compensation. The conversation covers negotiable elements like sign-on bonuses and long-term incentives. Anthony offers guidance on navigating non-compete and non-solicitation agreements, providing legal advice and identifying red flags in employment agreements. The episode concludes with reflections on the candidate's experience during the hiring process.

Anthony Greco, Talent Acquisition Lead at BMS discusses what you need to know about job offers and how to properly handle them.

Anthony shares….

👉 What should be included in an Offer Letter

👉 How to best negotiate a Job Offer

👉 Is it true to “Never Accept the First Offer”?

👉 How do sign on bonuses work and when can you expect one

👉 What does “At Will Employment” mean

👉 How to handle a “non compete” and why it differs from a “non solicitation”

Click for Source
job offer negotiations, compensation discussions, employment agreements, non-compete agreements, sign-on bonuses

Related Topics

Explore the Ecosystem

Meet Our Innovation Partners

You May Also Like

Podcast
COMP: How HR Determines Compensation and Titles for Job Offers
Partner Avatar MSL Talk: Tom Caravela, Chris Castin

COMP: How HR Determines Compensation and Titles for Job Offers

Mar 29th • 43 mins • listen
Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Apr 26th • 15 mins • read
Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Apr 16th • 28 mins • listen
Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Apr 13th • 10 mins • read
Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Dec 2nd • 2 mins • read
Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Nov 20th • 12 mins • read

Explore OVN

Articles Expert-written insights
Browse Ecosystem Oncology focus areas
OVN Podcast Flagship show
Community Why join OVN